About Event

Welcome to the 8th Dermatology Drug Development Summit

The 8th Dermatology Drug Development Summit is your definitive industry-led forum uniting a driven community trailblazing innovative drug discovery research and clinical strategy to collectively improve the long-term quality of life for patients with immuno-inflammatory disease.

Recognizing how disease heterogeneity and biomarker discovery is triggering a new wave of novel drug discovery efforts while clinical pipelines see increasing competition, staying ahead of the curve to develop differentiated candidates for novel inflammatory candidates has never been more important.

Showcasing the most novel targets, modalities, MoA and delivery approaches, 2024 brings you:

4 deep-dive workshops on progressing emerging candidates for Hidradenitis Suppurativa, JAK Inhibitor MoA, Indication Expansion Strategies, and Navigating Clinical Patient Recruitment & Retention Challenges
Increased content from 30+ organizations to effectively map the drug development landscape, including clinical pipeline case studies including dedicated Q&A time with Johnson & Johnson, Innovative Medicine, LEO Pharma, Sanofi and InflaRx to define pipeline strategies with late-stage programs in mind
Novel targets & translational techniques: discover research techniques driving immunologic heterogeneity and pathogenesis discoveries to uncover new therapeutic opportunities then translate to the clinic through novel models and assays with advanced predictive power in chronic disease
Clinical & commercial strategy: uncover creative clinical design with defined endpoints to hasten timelines, whilst demonstrate safety, efficacy and long-term improvements in QoL for Best-In-Class approvals

With the 2024 program design informed by industry experts, we can’t wait for you to join us for unmissable content highlights from Alys Pharmaceuticals, AbbVie, Recludix, Arcutis Biotherapeutics, and more industry innovators – Can your team afford to miss out?

Bringing You A More Diverse Landscape of Progressing Candidates Than Ever Before!

Therapeutic Pipeline Updates Include:

Atopic Dermatitis
Allopecia Areata
Vitiligo
Hidradenitis Suppurativa
Psoriasis
Chronic Spontaneous Urticaria
Pruigo
Bullous Pemphigoid
& More

Targets / Mechanism of Action:

Anti-IL7Ra
Anti-CXCL10
IL-13
OX40
IL-17
PDE4
C5aR
GPCR19-P2X7
JAK1
IL-23
DHODH
& More

Modality / Delivery Route:

Monoclonal Antibody
Oral Small Molecule
Topical
Oral Peptide
siRNA Lipid Conjugate
Bispecific Antibody
& More

Why Your Peers Are Participating:

“Bringing together thought leaders from academia, biotech and pharma with a common goal of improving the treatment armamentarium in dermatology”

Paul Smith, Senior Vice President, Biology, Recludix Pharma

“We are in the midst of transformative period in the treatment of inflammatory skin diseases- understanding the molecular underpinnings of disease and matching these to novel and highly effective therapies, but there is still much work to be done. The Dermatology Drug Development Summit will bring together experts from academia and industry alike to collaborate and carve a path forward such that we can continue bringing exciting new therapies to our patients.”

William Damsky, Assistant Professor of Dermatology & Pathology, Yale School of Medicine

The Dermatology Drug Development Summit is a vibrant forum for the presentation of innovation and ideas amongst experts who understand the unique opportunities and challenges of treating dermatologic disease. I am looking forward to the excitement and energy of discussions within the group to advance the field.”

David Chu, Vice President, Clinical Development, Arcutis Biotherapeutics

“An important forum to discuss the most pressing issues in dermatology drug development to ensure we best meet the needs of our patients.”

Kassim Rahawi, Global Medical, Director, Amlitelimab, Sanofi